[Articles] Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
Continuation of treatment beyond progression in the product labelling of these immunotherapies has not been recommended because the clinical benefit remains to be proven. Treatment beyond progression with anti-PD-1 antibody therapy might be appropriate for selected patients with unresectable or metastatic melanoma, identified by specific criteria at the time of progression, based on the potential for late responses in the setting of the known toxicity profile.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B Goldberg, Meredith K Chuk, Dow-Chung Chi, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M Blumenthal, Patricia Keegan, Richa Tags: Articles Source Type: research
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Immunotherapy | Melanoma | Skin Cancer | Toxicology